Business · Companies · 1 hr ago
Roche signs obesity drug licensing deal with China's Rona worth up to $1.16 billion
Roche has struck a licensing deal with China's Rona Therapeutics for an obesity drug.
The deal could be worth up to $1.16 billion.
Licensing deals give a company rights connected to a drug.
The headline does not identify the drug or explain the deal's terms.
It gives no details about how the companies will develop or market the drug.
No next steps are specified.
Roche signed an obesity drug licensing deal with China’s Rona Therapeutics.
The deal is worth up to $1.16 billion.
The deal concerns an obesity drug.
- Who
- Roche and China’s Rona Therapeutics.
- What
- They signed an obesity drug licensing deal worth up to $1.16 billion.
- When
- October 13, 2026, the date the report was published.
- Where
- Not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Companies
- Roche and Rona Therapeutics
- Drug area
- Obesity
- Deal value
- Up to $1.16 billion
Sources
Related news
China approves Visa to prepare a domestic bank card clearing business
EU-China trade talks leave the bloc’s widening deficit largely untouched
Saudi Arabia imposes anti-dumping duties on Chinese aluminum can lids
Visa gets approval for China card business ahead of Trump-Xi summit
EU and China agree to cap hybrid car imports at 350,000 a year
Fuyao founder urges Chinese firms expanding overseas to respect local rules
China and EU agree to cut hybrid car exports by more than half
Ola Dimensions raises hundreds of millions of RMB in fourth funding round
Chongqing expands electric car exports through rail and sea routes
Yichang moves sturgeon farming from river cages to indoor facilities
Shanghai shares rise as more than 2,900 stocks gain
